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ABSTRACT 44 
 45 
The contributions of coding mutations to tumorigenesis are relatively well known; 46 
however, little is known about somatic alterations in noncoding DNA. Here we describe GECCO 47 
(Genomic Enrichment Computational Clustering Operation) to analyze somatic noncoding 48 
alterations in 308 pancreatic ductal adenocarcinomas (PDAs) and identify commonly mutated 49 
regulatory regions. We find recurrent noncoding mutations are enriched in PDA pathways, 50 
including axon guidance and cell adhesion, and novel processes including transcription and 51 
homeobox genes. We identify mutations in protein binding sites correlating with differential 52 
expression of proximal genes and experimentally validate effects of mutations on expression. 53 
We developed an expression modulation score that quantifies the strength of gene regulation 54 
imposed by each class of regulatory elements, and find the strongest elements are most 55 
frequently mutated, suggesting a selective advantage. Our detailed single-cancer analysis of 56 
noncoding alterations identifies regulatory mutations as candidates for diagnostic and 57 
prognostic markers, and suggests novel mechanisms for tumor evolution. 58 
 59 
 60 
 61 
  62 
 3
INTRODUCTION 63 
 64 
Pancreatic ductal adenocarcinoma (PDA) is a highly lethal malignancy with a 5-year 65 
survival rate of 6%, due to therapy resistance and late stage at diagnosis1. A detailed 66 
understanding of the molecular alterations underlying PDA is required to uncover mechanisms 67 
of tumorigenesis and enable development of effective therapies. Exome sequencing efforts 68 
have revealed genes (KRAS, TP53, CDKN2A, SMAD4) and pathways (Wnt/Notch, transforming 69 
growth factor-β (TGF-β, axon guidance, cell adhesion) important for PDA progression2,3. 70 
However, the exome comprises less than 2% of the human genome. Whole-genome 71 
sequencing (WGS) analyses have uncovered an average somatic mutation rate of 2.64 72 
mutations per megabase in PDA indicating that PDA tumors often carry thousands of mutations, 73 
the vast majority of which are located in noncoding regions and are completely 74 
uncharacterized.4 75 
Relevance of noncoding mutations (NCMs) to cancer development was previously 76 
established with the discovery of highly recurrent mutations in the telomerase reverse 77 
transcriptase (TERT) promoter in sporadic and familial melanoma5,6. These mutations create 78 
binding motifs for ETS transcription factors and lead to increased TERT transcriptional activity5,7. 79 
Subsequent reports identified TERT promoter mutations in a wide-range of human tumors, 80 
including glioblastoma and hepatocellular carcinoma8. TERT promoter mutations are the most 81 
common genetic alterations in bladder cancer and correlate with recurrence and survival, 82 
demonstrating the potential of NCMs to act as clinical biomarkers9. NCMs have also been 83 
demonstrated to drive tumor progression from intergenic elements. Somatic mutations in a 84 
subset of T-cell acute lymphoblastic leukemia cases generate binding sites for the MYB 85 
transcription factor, creating a super-enhancer driving expression of the TAL1 oncogene10. 86 
Recent analyses have pooled WGS data from multiple cancer types and hundreds of patients, 87 
identifying recurrent mutations in regulatory elements of several genes, including TERT11-15. 88 
While multi-cancer studies can identify ubiquitous cancer variants, in-depth analysis of individual 89 
cancer subtypes is required for uncovering disease-specific alterations16.  90 
 To detect somatic NCMs in PDA, we developed a computational pipeline to analyze 91 
WGS data of 308 PDA tumors from the International Cancer Genome Consortium (ICGC)17. We 92 
used FunSeq218,19 to initiate prioritization of noncoding mutations, which revealed hundreds of 93 
thousands of noncoding somatic mutations with potential functional implications. To discriminate 94 
amongst this large number of NCMs, we developed GECCO (Genomic Enrichment 95 
Computational Clustering Operation) to identify candidate NCMs that drive differential gene 96 
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expression. This approach reduced the number of putative gene-proximal regulatory regions by 97 
three orders of magnitude to a set of high confidence calls. 98 
  Using GECCO, we identify novel recurrent mutations and interrogate expression data 99 
from matched tumors to find variants associated with changes in mRNA levels. We find 100 
significant differential expression of 16 genes associated with NCMs. For two of these genes, 101 
PTPRN2 and SLC12A8 we uncover previously unidentified clinical relevance in PDA. 102 
Specifically, we find that PTPRN2 expression level is an independent prognostic variable for 103 
overall patient survival. Pathway analysis of the genes associated with recurrent NCMs 104 
identifies known and novel PDA pathways. Furthermore, we find enrichment for mutations in 105 
specific regulatory regions, suggesting that NCMs may be acted upon by selection during tumor 106 
formation. Our analysis provides a model for tumor evolution via the formation and selection for 107 
alterations in noncoding regulatory elements of specific genes as a means of control over 108 
specific biological pathways.    109 
 110 
 111 
RESULTS 112 
 113 
To analyze NCMs in PDA, we selected all 405 patients with WGS data from the ICGC 114 
Pancreatic Cancer Genome Project. We determined the total number of somatic single 115 
nucleotide variants (SNV) and small insertions or deletions (indels) for each patient, and 116 
retained those with mutation load no greater or less than 3 standard deviations from the mean 117 
(mean=7,937; range=1-440,471) to exclude the hyper-mutated tumors with unlocalized 118 
replication defects (Fig. 1a, Supplementary Fig. 1). In total, 2,248,158 SNVs/indels from 308 119 
PDA patient samples were kept for analysis.  120 
 121 
General features of GECCO 122 
To discover the effect of noncoding mutations on PDA progression and patient outcome 123 
we developed the computational pipeline GECCO (Fig. 2). GECCO begins by selecting 124 
noncoding mutations falling within The Encyclopedia of DNA Elements20 (ENCODE)-defined 125 
transcription factor binding peaks – hereby referred to as cis-regulatory regions (CRRs) as not 126 
all proteins profiled are transcription factors and may be part of larger regulatory complexes – 127 
and then proceeds with downstream processing in two parallel modules. We define a “CRR 128 
class” to be all CRRs that are bound by the same DNA-binding protein (i.e. CTBP2, with 1781 129 
CRRs across the genome) or proteins involved in DNA-binding complexes (i.e. SUZ12, with 130 
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1618 CRRs across the genome). The first module of GECCO associates NCMs with proximal 131 
genes and uses permutation testing to identify highly mutated clusters that correlate significantly 132 
with changes in gene expression. The second module calculates the mutation rate of each CRR 133 
to determine which specific CRR classes are more commonly mutated in PDA. 134 
In the second module, GECCO computes an expression modulation score (EMS) using 135 
coupled gene expression data to determine the regulatory impact of each CRR class. The EMS 136 
can be used to generate a rank sorted list of CRRs based on the strength of their relative gene 137 
regulatory impact (such that the strongest activators and repressors fall at both ends of the list). 138 
Taken together, the results generated from GECCO provide information on the impact of NCMs 139 
on the expression level of individual genes and identifies potential driver transcription factors. 140 
Finally, GECCO merges the results of both modules to perform pathway and clinical survival 141 
analysis, allowing novel insights into PDA biology and patterns of somatic mutations in cancer. 142 
 143 
Prioritization of non-coding mutations 144 
We first identified NCMs in the exact same genomic position in multiple patients and 145 
removed common human variants (MAF > 5% in 1000 Genome Phase I) (Supplementary 146 
Table 1). This identified several variants reaching over 2% incidence (n ≥ 7 out of 308 patients) 147 
in the patient cohort (Supplementary Table 1). Among the 11 genes associated with these 148 
variants, 6 have been implicated in tumorigenesis, including WASF321, BNC222, ELMO123, 149 
GPR9824, PDE3B25 and SOX526. Interestingly, 10 of 11 of these mutations were found in introns. 150 
However, none of the exactly recurrent mutations disrupted, or created, transcription factor-151 
binding motifs (as defined by the JASPAR transcription factor binding profile database27) or fell 152 
within known regulatory elements. This analysis is consistent with several pan-cancer analyses 153 
that found few exactly recurrent mutations outside of the well-characterized TERT promoter 154 
mutations11,12. 155 
We extended this analysis by prioritizing NCMs by their association with functional 156 
annotations and clustering within regulatory elements. We used the FunSeq2 computational 157 
pipeline18,19 as a high-level filter to remove common variants and identify putative somatic 158 
regulatory mutations with functional impact. One important benefit of this approach is that it 159 
relies on functional information and thus drastically reduces any biases resulting from non-160 
homogeneous mutation rates across the genome. This initial round of filtering identified 301,596 161 
potential somatic drivers across all 308 patients (mean=1,988; range=203-17,902) (Fig. 1b). 162 
264,488 of the somatic NCMs fell within ENCODE-defined transcription factor-binding peaks, 163 
with the majority of the remaining mutations within enhancers (19,608) or DNaseI hypersensitive 164 
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sites (DHSs) (14,572) (Fig. 1b). We focused our analysis on the 264,488 NCMs within the 165 
ENCODE-defined CRRs. There was a direct correlation between CRR mutation rate and total 166 
SNVs (Fig. 1c). In contrast, no correlations between CRR mutation rate and coding mutations in 167 
KRAS, TP53, CDKN2A, SMAD4, and ARID1A were observed (Supplementary Fig. 3). 168 
 169 
Analysis of cis-regulatory mutations    170 
Starting with 264,488 candidate mutations, we used GECCO to focus our analysis on 171 
CRRs within 2kb of each gene (many of which overlap promoters), seeking to identify clusters of 172 
mutations in CRRs that directly impact gene expression (Fig. 3a). The requirement to be within 173 
2kb of a gene excludes many distal enhancer regions but increases the likelihood that a given 174 
CRR topologically associates with, and therefore regulates, the expression of its proximal gene. 175 
The most frequently mutated CRR (17 patients, 5.52% of cohort) was in a TCF12-binding region 176 
proximal to LHX8 (LIM homeobox 8) (Fig. 3a). LHX8, a homeobox gene and regulator of 177 
craniofacial development, modulates the Hedgehog pathway, a known regulator of PDA 178 
pathogenesis28. We observed a cluster of mutations in a E2F1-binding region in proximity to 179 
BMP7 (bone morphogenetic protein 7). BMP7 is a TGF-βfamily member, with pleiotropic roles 180 
in development and cancer progression29. GECCO did not detect any recurrent variants in the 181 
TERT promoter, in concordance with a previous study that failed to detect TERT promoter 182 
mutations in 24 PDA samples8. To determine if the identified NCMs were within active 183 
promoters or enhancers in pancreatic cells, we interrogated H3K4me3 and H3K27ac regions 184 
from ENCODE in pancreatic carcinoma-derived PANC-1 cells. In PANC-1 cells, 37.6% of all 185 
transcription factor-binding peaks were found within active PANC-1-predicted promoters or 186 
enhancers. In contrast, 58.9% of recurrent NCMs (>5 patients) were found within at least one 187 
PANC-1-predicted active promoter or enhancer. The CRRs with recurrent NCMs did not differ 188 
significantly in size from those lacking recurrent NCMs. Therefore, recurrent NCMs are enriched 189 
in transcriptionally active regions of the genome in pancreatic cancer cells.  190 
We identified clusters of NCMs in regulatory regions of long intergenic non-protein 191 
coding RNAs (lncRNAs), including the oncogenic lncRNA Metastasis Associated Lung 192 
Adenocarcinoma Transcript 1 (MALAT1)30, and in microRNAs, including the oncogenic miR-2131 193 
(Fig. 3a). To infer functional consequences of the most recurrently mutated gene-proximal 194 
CRRs, we used data from a published in vitro short hairpin RNA (shRNA) screen, which 195 
monitored survival in 102 cell lines, of which 13 were pancreas cancer-derived32. Knockdown of 196 
6 (LHX8, LMX1B, PAX6, DMRTA2, VAX2, CDH15) of the top 15 genes was found to decrease 197 
cancer cell survival, providing potential functional relevance for these genes as cancer drivers 198 
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(Fig. 3a). Knockdown of two genes, LMX1B and CDH15, showed selective killing of PDA cell 199 
lines amongst all cancers, suggesting tumor-specific vulnerabilities. 200 
To control for variable CRR size, we calculated a mutational frequency for each cluster 201 
harboring at least 5 mutations, defined as the number of mutations across all patients divided by 202 
the number of nucleotides spanning the cluster (Fig. 3b). The highest scoring result was an 203 
exactly recurrent mutation in the same genomic position in 5 patients, flanking the acyl-CoA 204 
oxidase-like gene ACOXL, a known susceptibility locus for chronic lymphocytic leukemia33. This 205 
mutation was not found to be within a known transcription factor-binding site as defined by 206 
JASPAR. We also identified a cluster of 5 mutations within 19 nucleotides proximal to the 207 
neuronal cell adhesion gene NRXN3, a regulator of glioma cell proliferation and migration34. 208 
While multi-cancer recurrent NCMs have been described11,12, we lack an understanding 209 
of their mutational patterns. For example, it is unknown if NCMs cluster near the same genes 210 
that show recurrent coding mutations for a given disease. Therefore, we looked for clusters of 211 
NCMs in association with known PDA genes, present in at least 5 patients (Supplementary 212 
Table 2). We did not detect any recurrent NCMs in CRRs within 2kb of KRAS, TP53, CDKN2A, 213 
SMAD4, ARID1A and MLL3, in addition to 24 of 26 other PDA genes identified from previous 214 
whole exome analyses (Supplementary Table 2)2,3. This result is consistent with defects in 215 
protein function, rather than alterations in expression, in the pathogenesis of these PDA genes. 216 
 217 
Novel clinical outcomes from pathway analysis 218 
Pathway analysis of recurrently mutated PDA genes has been used to identify signaling 219 
networks and biological processes underlying disease pathogenesis2,3. To detect patterns in 220 
NCM localization at the pathway level, we utilized The Database for Annotation, Visualization 221 
and Integrated Discovery (DAVID), a functional annotation enrichment algorithm for large-scale 222 
biological datasets35. Pathway analysis of genes near CRRs containing clusters of mutations 223 
(>5 patients) identified significant enrichment of several gene families and regulatory processes, 224 
including transcriptional regulation, homeobox genes, axon guidance, cell adhesion and Wnt 225 
signaling (Fig. 3c). The involvement of three of these pathways (axon guidance, cell adhesion, 226 
Wnt signaling) in PDA has been identified from previous exome sequencing studies2,3. 227 
Furthermore, several homeobox genes and transcription factors have been implicated in PDA 228 
pathogenesis, including PAX636, HOXB237, HOXB738 and RUNX339. Therefore, NCMs display 229 
preferential patterns of localization in the PDA genome and, although not found near canonical 230 
PDA genes, may act through modulation of canonical PDA pathways. In addition, we uncover a 231 
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previously unrecognized localization of NCMs near transcriptional regulators and homeobox 232 
genes, suggesting a role for these factors in PDA.  233 
The availability of matched gene expression data from a large number (n=96) of patient 234 
samples allowed association studies between specific clusters of mutations and changes in 235 
gene expression. For each of the 124,075 CRRs we determined differential gene expression 236 
between patients with mutations in a proximal CRR compared to patients without mutations. 237 
Using permutation testing we identified NCMs that significantly impacted expression of their 238 
proximal gene and calculated their false discovery rates (for details, see Online Methods). 239 
Many of the genes with the greatest number of mutations (Fig. 3a) did not reveal significant 240 
changes in gene expression. However, this analysis yielded 16 NCMs associated with 241 
significant changes in gene expression (≥3 patients, p<0.05, FDR<0.25) (Fig. 4a). Eight of the 242 
16 NCMs were present in regions marked by H3K4me3 and H3K27ac in PANC-1 cells. None of 243 
the statistically significant mutations were associated with increases in gene expression. Three 244 
of the genes with statistically significant decreases in expression (KCNQ1, IKZF1, TUSC7) have 245 
been implicated as tumor suppressors40,41, while two (PTPRN2, SNRPN) are frequently 246 
hypermethylated42,43. Next, we looked for correlations between NCM-associated differential 247 
expression and clinical correlates in PDA. The small sample size precluded identification of 248 
specific NCMs associated with differences in patient outcome. Therefore, we looked for 249 
associations between expression of these 16 genes and patient outcome. Low mRNA 250 
expression of the phosphatase PTPRN2 and the ion transporter SLC12A8 were associated with 251 
decreased overall survival and decreased disease-free survival in a univariate analysis, 252 
respectively (Fig. 4b,c). Furthermore, a multivariate analysis revealed PTPRN2 as an 253 
independent prognostic variable for overall survival (Supplementary Table 3). 254 
 255 
Mechanisms of NCM-modulated expression 256 
To uncover mechanisms by which expression-correlated SNPs may influence 257 
transcription, we annotated mutations with their predicted influence on local DNase 258 
hypersensitivity using the software Basset44 (see Online Methods). The predicted influences of 259 
these 55 SNPs were significantly greater in magnitude after Bonferroni correction than a null 260 
model of sampling from the full set in 160 out of 164 examined cell types. For example, two 261 
different mutations in IRF1 and PRDM1 motifs altered critical positions that likely debilitate 262 
binding within an intron of SLC12A8 (Fig. 4d). Additional mutations modulate an NRF1 motif in 263 
the promoter of SNRPN and a GATA motif adjacent to a PU.1 binding site in an intron of 264 
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LSAMP (Supplementary Fig. 4). Therefore, GECCO enriches for NCMs with predicted effects 265 
on DNase hypersensitivity and transcription factor binding.   266 
While the Basset analysis identified NCMs predicted to affect DNase hypersensitivity, we 267 
sought to uncover NCMs directly modulating gene expression. To determine the functional 268 
relevance of specific NCMs, we performed luciferase reporter assays in non-transformed HEK-269 
293 cells and the MiaPaCa2 and Suit2 PDA cell lines, comparing gene expression driven by 270 
wild type (WT) and mutant (MUT) sequences (Fig. 5). Among 11 regions tested, 7 (293) and 4 271 
(MiaPaCa2, Suit2) mutations significantly altered luciferase expression. Importantly, NCMs 272 
associated with PTPRN2, PDPN, TUSC7, SNRNP and MTERF4 significantly decreased 273 
luciferase expression in one or multiple cell lines, consistent with decreased expression of these 274 
genes associated with NCMs in patient samples (Fig. 4a). Our validation rate was greater or 275 
comparable in terms of hit rate, and greater in terms of fold change, than other recent attempts 276 
to identify NCMs driving differential expression15,16, highlighting the power of GECCO to identify 277 
functionally significant NCMs from millions of candidate mutations.    278 
 279 
Mutational and expression patterns of CRR classes 280 
 The second module of GECCO focuses on CRR classes, rather than individual genes, to 281 
identify mutational patterns and overall effects on gene expression of each CRR class (Figure 282 
6). We computed the mutation rate for each CRR class correcting for element size and 283 
abundance in the genome. We found no significant effect of GC content on CRR class mutation 284 
rate. Noncoding mutations were specifically enriched in certain classes of gene-proximal CRRs 285 
(see Supplementary Note). Next, we sought to understand the molecular characteristics of 286 
each CRR class in terms of effect on gene expression. We calculated an expression modulation 287 
score (EMS) for each CRR class reflecting the impact of the presence of that CRR on the 288 
expression of the neighboring gene in relation to all other genes.  This method compared, for 289 
each CRR class, mean expression of genes proximal to a CRR to those that are non-proximal.  290 
CRRs with strong predicted activating or repressing activity would be proximal to genes with 291 
expression levels substantially higher (for activators) or substantially lower (for repressors) than 292 
the basal genome expression level (Supplementary Table 4, see Online Methods). To 293 
determine if the strongest activators and repressors were enriched for those CRRs with the 294 
highest mutational frequencies, we considered any activator or repressor that was greater than 295 
1 standard deviation from the mean EMS (12 activators, 9 repressors) (Fig. 6, green and 296 
orange bars). The mutational frequencies for each group (activators, repressors, all others with 297 
balanced expression) were then calculated and activators and repressors compared to the 298 
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balanced group (p=0.02077 for activators vs. balanced; p=0.04982 for repressors vs. balanced). 299 
The CRR classes with the highest percentage of mutations across all PDA patients were 300 
enriched on either end of the spectrum (most repressive or most active), suggesting that 301 
recurrent NCMs are preferentially located in CRR classes with the strongest impact on gene 302 
expression. These highly active CRR classes have the largest effect on gene expression and 303 
may, therefore, confer a selective advantage to the cell. In addition, we noted that the 6 genes 304 
identified from the shRNA survival screen (Fig. 3a) were all associated with NCMs in highly 305 
repressive CRRs.. In contrast, every gene that failed to score in the shRNA survival screen was 306 
associated with highly active CRRs (Fig. 3a).  307 
 308 
Pathway dynamics between activating and repressing CRRs 309 
Next, we investigated the patterns of noncoding SUZ12 mutations in our patient cohort, 310 
as SUZ12 had the highest repressive score and SUZ12 sites were frequently mutated 311 
(Supplementary Table 4, Fig. 6). We generated two distinct lists of SUZ12-associated genes. 312 
The first list contained those genes associated with recurrently mutated SUZ12 sites. The 313 
second list contained those genes associated with SUZ12 sites that never harbored recurrent 314 
NCMs. We then performed pathway analysis on each gene set to identify differences in 315 
biological functions (Fig. 7a). We found that genes without recurrent SUZ12 mutations were 316 
enriched in glycoproteins, intracellular signaling as well as the axon guidance/neuron 317 
differentiation pathway. In contrast, genes with recurrent SUZ12 mutations were more 318 
significantly enriched in homeobox genes, transcription factors, Wnt signaling, proto-oncogenes 319 
and the axon guidance/neuron differentiation pathway. Surprisingly, several categories, 320 
including glycoproteins, intracellular signaling and extracellular matrix, were completely absent 321 
within the mutant SUZ12 gene set. Therefore, there is specificity for the location of NCMs in 322 
PDA, not only for certain CRRs, but also for the corresponding cancer-associated genes and 323 
pathways. 324 
To further characterize pathways downstream of commonly mutated repressive CRRs, 325 
we performed pathway analysis on genes with and without associated CTBP2 mutations (Fig. 326 
7a). Genes without CTBP2 noncoding mutations showed a similar pattern of pathway regulation 327 
as SUZ12.. These pathways were markedly enriched in the gene set associated with CTBP2 328 
mutations, while alternative splicing and glycoproteins were completely absent. We extended 329 
this analysis to another repressive CRR with a high mutational frequency, SETDB1 (Fig. 6a). 330 
Genes associated with recurrent NCMs in SETDB1 binding sites were enriched in axon 331 
guidance/neuron differentiation, cell adhesion and disease mutation pathways. Therefore, 332 
 11
mutations in highly repressive CRRs are enriched in PDA and selectively associated with genes 333 
regulating a core set of biological processes.  334 
We performed a similar analysis for the commonly mutated activator CRRs, including 335 
KAT2A, BCLAF1, TAF7 and WRNIP1 (Fig. 7b) and again found specificity for the genes and 336 
pathways that are commonly mutated. For all CRRs, there were significant differences in the 337 
pathways regulated by genes with or without mutations in a given CRR. KAT2A, BCLAF1 and 338 
TAF7 shared a very similar pattern of pathway regulation, with significant increases in 339 
nucleosome assembly/organization, methylation and ubiquitin conjugation, all processes 340 
involved in chromatin dynamics. This suggests that genes associated with NCMs in 341 
transcriptional repressors regulate homeobox genes and PDA-associated pathways, while 342 
genes associated with NCMs in transcriptional activators may regulate transcriptional dynamics 343 
through modulation of chromatin states.  344 
 345 
 346 
DISCUSSION 347 
  348 
We developed a new computational method, GECCO, to systematically analyze the 349 
noncoding genome of PDA to uncover recurrent regulatory somatic mutations. We find patterns 350 
of NCMs associated with genes regulating canonical PDA pathways, but not associated with 351 
commonly mutated PDA genes. Therefore, NCMs may serve as a novel mechanism in cancer 352 
cells for regulating pathways critical for tumorigenesis. Furthermore, GECCO uncovers 353 
mutations correlated with changes in gene expression, including several known tumor 354 
suppressors and aberrantly methylated genes. GECCO produces a set of high confidence calls 355 
that enrich for predicted effects on DNase hypersensitivity and transcription factor binding, as 356 
well as functional effects on gene expression, as experimentally demonstrated by luciferase 357 
reporter assays. We find enrichment for NCMs in specific CRRs and distinct subsets of 358 
pathways associated with NCMs in highly repressive and transcriptionally active CRRs as 359 
identified by our EMS algorithm. To our knowledge, this is the first comprehensive analysis of 360 
noncoding alterations in PDA, providing novel insights into PDA pathogenesis and serving as a 361 
counterpart to the information gleaned from large-scale exome sequencing projects2,3. 362 
Mutational analysis of patient tumors is increasingly informing treatment decisions, 363 
whereas complimentary techniques, including microarray, RNA sequencing, fluorescence in situ 364 
hybridization and immunohistochemistry are required to analyze changes in gene or protein 365 
expression of cancer drivers that lack coding mutations. As somatic mutations in DNA 366 
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regulatory elements can alter gene expression of cancer drivers, targeted or whole genome 367 
sequencing may provide clinically useful information for these patients, both in terms of 368 
therapeutic decisions and clinical prognosis. Our analysis provides the first collection of NCMs 369 
that correlate with changes in gene expression in PDA. Furthermore, we uncover clinical 370 
outcome relationships for PTPRN2 and SLC12A8, neither of which has previously been 371 
implicated in PDA.  372 
Functional validation of NCM-gene expression associations is a critical step in evaluating 373 
the robustness of an analysis pipeline. Our luciferase reporter assay experiments demonstrated 374 
that GECCO has a higher validation rate in cancer cell lines than any recent study of NCMs15,16. 375 
Furthermore, the validation rate in HEK293 cells, a standard cell line for luciferase assays, was 376 
64%, concordant with the expected false discovery rate. Finally, GECCO accurately predicted 377 
the directionality of gene expression changes associated with NCMs. NCMs associated with 378 
PTPRN2, PDPN, TUSC7, SNRNP and MTERF4 significantly decreased luciferase expression in 379 
one or multiple cells lines, consistent with decreased gene expression of these genes 380 
associated with NCMs in patient samples. This is in contrast to a recent report where the 381 
directionality of gene expression changes in the luciferase assay was not consistent with the 382 
predicted response16. Therefore, GECCO represents a significant improvement in the ability to 383 
identify functionally relevant NCMs.  384 
Pathway analysis of the gene lists generated by GECCO revealed several unexpected 385 
findings. Strikingly, we found that the most highly recurrent somatic NCMs were located near 386 
genes in known PDA-associated pathways, including axon guidance, cell adhesion and Wnt 387 
signaling, but not the most commonly mutated PDA genes.. This suggests that NCMs may drive 388 
tumor progression through modulation of PDA-specific pathways, providing an alternative route 389 
for pathway activation and a novel mechanism of tumorigenesis. Furthermore, we provide 390 
evidence that NCMs in specific regulatory element classes are selected for during tumor 391 
evolution. These highly mutated regulatory element classes are predominantly those with the 392 
greatest impact on gene expression. Therefore, clusters of NCMs are enriched in gene-proximal 393 
regions with the greatest regulatory impact, again providing evidence for selection during 394 
tumorigenesis.  395 
Pathway analysis of genes near NCMs within these highly mutated regulatory regions 396 
shows selectivity for PDA pathways. These pathways are not enriched when analyzing genes 397 
without associated clusters of NCMs, again arguing in favor of selection. Interestingly, many 398 
transcriptional regulators bind selectively to different regions of the genome in malignant versus 399 
non-neoplastc cells45. We propose that NCMs found within promoters of PDA pathway genes 400 
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modify regulatory factor binding to alter gene transcription, thereby providing an additional 401 
mechanism to promote cancer. 402 
 403 
  404 
 14
DATA AVAILABILITY STATEMENT 405 
All data used in this analysis were downloaded from the International Cancer Genome 406 
Consortium (IGCG) data portal (https://dcc.icgc.org/projects). At our last date of access (Feb 11, 407 
2015), simple somatic mutations (SSM) for 405 pancreatic ductal adenocarcinoma samples 408 
were available from the Australian (PACA-AU) and Canadian (PACA-CA) groups. We download 409 
the clinical data, SSMs, and when available, sequence-based gene expression (EXP-S) data for 410 
all 405 patients. 411 
 412 
ACKNOWLEDGEMENTS 413 
The authors wish to thank the members of the Tuveson lab, C. Vakoc and A. Siepel for 414 
helpful discussions. DAT is a distinguished scholar of the Lustgarten Foundation and Director of 415 
the Lustgarten Foundation-designated laboratory of Pancreatic Cancer Research. DAT is also 416 
supported by the Cold Spring Harbor Laboratory Association, the Carcinoid Foundation, PCUK, 417 
and the David Rubinstein Center for Pancreatic Cancer Research at MSKCC. In addition, we 418 
are grateful for support from the following: the STARR foundation (I7-A718 for DAT), DOD 419 
(W81XWH-13-PRCRP-IA for DAT), Louis Morin Charitable Trust (MEF) and the NIH 420 
(5P30CA45508-26, 5P50CA101955-07, 1U10CA180944-01, 5U01CA168409-3, and 421 
1R01CA190092-01 for DAT and R01HG006677 for MCS).  422 
 423 
AUTHOR CONTRIBUTIONS 424 
Wrote the manuscript: MEF, TG, MCS, DAT 425 
Supervised the study: MCS, DAT 426 
Performed FunSeq analysis and developed GECCO: TG 427 
Performed pathway analysis: MEF 428 
Contributed to data analysis: MEF, TG, SMG, AVB, EK, SS, LDS, SG, JDM 429 
Performed patient outcome analysis: DC, PB 430 
Performed Basset analysis: DRK 431 
Performed germline sequence analysis: NW 432 
 433 
 434 
COMPETING FINANCIAL INTERESTS STATEMENT 435 
The authors declare no competing financial interests.  436 
 15
REFERENCES 437 
 438 
1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA: a cancer journal for 439 
clinicians 63, 11-30 (2013). 440 
2. Jones, S., et al. Core signaling pathways in human pancreatic cancers revealed by 441 
global genomic analyses. Science 321, 1801-1806 (2008). 442 
3. Biankin, A.V., et al. Pancreatic cancer genomes reveal aberrations in axon guidance 443 
pathway genes. Nature 491, 399-405 (2012). 444 
4. Waddell, N., et al. Whole genomes redefine the mutational landscape of pancreatic 445 
cancer. Nature 518, 495-501 (2015). 446 
5. Huang, F.W., et al. Highly recurrent TERT promoter mutations in human melanoma. 447 
Science 339, 957-959 (2013). 448 
6. Horn, S., et al. TERT promoter mutations in familial and sporadic melanoma. Science 449 
339, 959-961 (2013). 450 
7. Bell, R.J., et al. The transcription factor GABP selectively binds and activates the 451 
mutant TERT promoter in cancer. Science (2015). 452 
8. Killela, P.J., et al. TERT promoter mutations occur frequently in gliomas and a subset 453 
of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 454 
110, 6021-6026 (2013). 455 
9. Rachakonda, P.S., et al. TERT promoter mutations in bladder cancer affect patient 456 
survival and disease recurrence through modification by a common polymorphism. 457 
Proc Natl Acad Sci U S A 110, 17426-17431 (2013). 458 
10. Mansour, M.R., et al. An oncogenic super-enhancer formed through somatic 459 
mutation of a noncoding intergenic element. Science 346, 1373-1377 (2014). 460 
11. Weinhold, N., Jacobsen, A., Schultz, N., Sander, C. & Lee, W. Genome-wide analysis of 461 
noncoding regulatory mutations in cancer. Nat Genet 46, 1160-1165 (2014). 462 
12. Fredriksson, N.J., Ny, L., Nilsson, J.A. & Larsson, E. Systematic analysis of noncoding 463 
somatic mutations and gene expression alterations across 14 tumor types. Nat Genet 464 
46, 1258-1263 (2014). 465 
13. Melton, C., Reuter, J.A., Spacek, D.V. & Snyder, M. Recurrent somatic mutations in 466 
regulatory regions of human cancer genomes. Nat Genet (2015). 467 
14. Mathelier, A., et al. Cis-regulatory somatic mutations and gene-expression alteration 468 
in B-cell lymphomas. Genome biology 16, 84 (2015). 469 
15. Araya, C.L., et al. Identification of significantly mutated regions across cancer types 470 
highlights a rich landscape of functional molecular alterations. Nat Genet 48, 117-471 
125 (2016). 472 
16. Fujimoto, A., et al. Whole-genome mutational landscape and characterization of 473 
noncoding and structural mutations in liver cancer. Nat Genet 48, 500-509 (2016). 474 
17. International Cancer Genome, C., et al. International network of cancer genome 475 
projects. Nature 464, 993-998 (2010). 476 
18. Khurana, E., et al. Integrative annotation of variants from 1092 humans: application 477 
to cancer genomics. Science 342, 1235587 (2013). 478 
19. Fu, Y., et al. FunSeq2: A framework for prioritizing noncoding regulatory variants in 479 
cancer. Genome biology 15, 480 (2014). 480 
20. Consortium, E.P. An integrated encyclopedia of DNA elements in the human genome. 481 
Nature 489, 57-74 (2012). 482 
 16
21. Teng, Y., Mei, Y., Hawthorn, L. & Cowell, J.K. WASF3 regulates miR-200 inactivation 483 
by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast 484 
cancer cells. Oncogene 33, 203-211 (2014). 485 
22. Winham, S.J., et al. Genome-wide investigation of regional blood-based DNA 486 
methylation adjusted for complete blood counts implicates BNC2 in ovarian cancer. 487 
Genetic epidemiology 38, 457-466 (2014). 488 
23. Dulak, A.M., et al. Exome and whole-genome sequencing of esophageal 489 
adenocarcinoma identifies recurrent driver events and mutational complexity. Nat 490 
Genet 45, 478-486 (2013). 491 
24. Sherman, S.K., et al. Gastric inhibitory polypeptide receptor (GIPR) is a promising 492 
target for imaging and therapy in neuroendocrine tumors. Surgery 154, 1206-1213; 493 
discussion 1214 (2013). 494 
25. Uzawa, K., et al. Targeting phosphodiesterase 3B enhances cisplatin sensitivity in 495 
human cancer cells. Cancer medicine 2, 40-49 (2013). 496 
26. Renjie, W. & Haiqian, L. MiR-132, miR-15a and miR-16 synergistically inhibit 497 
pituitary tumor cell proliferation, invasion and migration by targeting Sox5. Cancer 498 
letters 356, 568-578 (2015). 499 
27. Sandelin, A., Alkema, W., Engstrom, P., Wasserman, W.W. & Lenhard, B. JASPAR: an 500 
open-access database for eukaryotic transcription factor binding profiles. Nucleic 501 
acids research 32, D91-94 (2004). 502 
28. Flandin, P., et al. Lhx6 and Lhx8 coordinately induce neuronal expression of Shh that 503 
controls the generation of interneuron progenitors. Neuron 70, 939-950 (2011). 504 
29. Boon, M.R., et al. Bone morphogenetic protein 7: a broad-spectrum growth factor 505 
with multiple target therapeutic potency. Cytokine & growth factor reviews 22, 221-506 
229 (2011). 507 
30. Gutschner, T., et al. The noncoding RNA MALAT1 is a critical regulator of the 508 
metastasis phenotype of lung cancer cells. Cancer Res 73, 1180-1189 (2013). 509 
31. Moriyama, T., et al. MicroRNA-21 modulates biological functions of pancreatic 510 
cancer cells including their proliferation, invasion, and chemoresistance. Molecular 511 
cancer therapeutics 8, 1067-1074 (2009). 512 
32. Cheung, H.W., et al. Systematic investigation of genetic vulnerabilities across cancer 513 
cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci 514 
U S A 108, 12372-12377 (2011). 515 
33. Lan, Q., et al. Genetic susceptibility for chronic lymphocytic leukemia among Chinese 516 
in Hong Kong. European journal of haematology 85, 492-495 (2010). 517 
34. Sun, H.T., Cheng, S.X., Tu, Y., Li, X.H. & Zhang, S. FoxQ1 promotes glioma cells 518 
proliferation and migration by regulating NRXN3 expression. PLoS One 8, e55693 519 
(2013). 520 
35. Huang da, W., Sherman, B.T. & Lempicki, R.A. Systematic and integrative analysis of 521 
large gene lists using DAVID bioinformatics resources. Nature protocols 4, 44-57 522 
(2009). 523 
36. Mascarenhas, J.B., et al. PAX6 is expressed in pancreatic cancer and actively 524 
participates in cancer progression through activation of the MET tyrosine kinase 525 
receptor gene. J Biol Chem 284, 27524-27532 (2009). 526 
 17
37. Segara, D., et al. Expression of HOXB2, a retinoic acid signaling target in pancreatic 527 
cancer and pancreatic intraepithelial neoplasia. Clinical cancer research : an official 528 
journal of the American Association for Cancer Research 11, 3587-3596 (2005). 529 
38. Chile, T., et al. HOXB7 mRNA is overexpressed in pancreatic ductal adenocarcinomas 530 
and its knockdown induces cell cycle arrest and apoptosis. BMC cancer 13, 451 531 
(2013). 532 
39. Whittle, M.C., et al. RUNX3 Controls a Metastatic Switch in Pancreatic Ductal 533 
Adenocarcinoma. Cell 161, 1345-1360 (2015). 534 
40. Than, B.L., et al. The role of KCNQ1 in mouse and human gastrointestinal cancers. 535 
Oncogene 33, 3861-3868 (2014). 536 
41. Geimer Le Lay, A.S., et al. The tumor suppressor Ikaros shapes the repertoire of 537 
notch target genes in T cells. Science signaling 7, ra28 (2014). 538 
42. Anglim, P.P., et al. Identification of a panel of sensitive and specific DNA methylation 539 
markers for squamous cell lung cancer. Molecular cancer 7, 62 (2008). 540 
43. Benetatos, L., et al. CpG methylation analysis of the MEG3 and SNRPN imprinted 541 
genes in acute myeloid leukemia and myelodysplastic syndromes. Leukemia 542 
research 34, 148-153 (2010). 543 
44. Kelley, D.R., Snoek, J. & Rinn, J.L. Basset: learning the regulatory code of the 544 
accessible genome with deep convolutional neural networks. Genome research 26, 545 
990-999 (2016). 546 
45. Squazzo, S.L., et al. Suz12 binds to silenced regions of the genome in a cell-type-547 
specific manner. Genome research 16, 890-900 (2006). 548 
46. Weirauch, M.T., et al. Determination and inference of eukaryotic transcription factor 549 
sequence specificity. Cell 158, 1431-1443 (2014). 550 
47. Gupta, S., Stamatoyannopoulos, J.A., Bailey, T.L. & Noble, W.S. Quantifying similarity 551 
between motifs. Genome biology 8, R24 (2007). 552 
 553 
 554 
  555 
 18
FIGURE LEGENDS 556 
 557 
Figure 1 - Identification of recurrent noncoding mutations in PDA. 558 
(a) The total number of single nucleotide variants (SNV) was plotted for each patient. (b) 559 
FunSeq2 was utilized to detect and characterize putatitve somatic noncoding mutations from 560 
308 PDA whole genome sequences. Mutation counts for each functional category are displayed. 561 
(c) The number of cis-regulatory region (CRR) mutations (grey bars), and CRR/total SNV (black 562 
points) were plotted for each patient.  563 
 564 
Figure 2 - GECCO (Genomic Enrichment Computational Clustering Operation) flowchart. 565 
GECCO utilizes noncoding somatic mutation calls from tumor whole genome sequencing data 566 
to identify clusters of mutations within 2kb of genes, including those that correlate with changes 567 
in gene expression. GECCO also calculates the mutation rate of gene regulatory regions and 568 
determines the strength of each regulatory region in terms of the effect on gene expression 569 
(expression modulation score, EMS). These data can then be used for pathway analysis of 570 
genes proximal to noncoding clusters and genes downstream of specific regulatory regions. The 571 
gene lists can also be interrogated for patient survival analysis when coupled to outcome data 572 
for detection of clinically relevant interactions. 573 
 574 
Figure 3 - Clustered gene-proximal mutations and pathways in PDA. 575 
(a) The most common mutational clusters across the patient cohort as determined by GECCO, 576 
with associated genes; Yes = knockdown promoted cell death in shRNA cancer cell line screen. 577 
(P denotes PDA-specific); No = no evidence for effect on cell death in shRNA cancer cell line 578 
screen. (b) Most significant clusters when corrected for cluster size as determined by GECCO. 579 
(c) DAVID pathway analysis was used to identify regulatory processes and pathways from 580 
genes associated with recurrent NCMs.  581 
 582 
Figure 4 - Recurrent gene-proximal mutations correlate with gene expression changes in 583 
PDA.  584 
(a) GECCO used gene expression data from matched PDA patients to correlate NCMs with 585 
changes in gene expression “Mut allele” = mean expression of linked gene in patients with 586 
associated CRR mutations. “WT allele” = mean expression of linked gene in patients without 587 
associated CRR mutations. (b) Analysis of overall survival (OS) in PDA patients expressing high  588 
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(upper 2/3) and low (lower 1/3) levels of PTPRN2. Purple dots represent patients with high 589 
expression of PTPRN2 “at risk” (alive). Red dots represent patients with low expression of 590 
PTPRN2 “at risk” (alive). (c) Analysis of disease-free survival (DFS) in PDA patients expressing 591 
high (upper 2/3) and low (lower 1/3) levels of SLC12A8. (d) Two A→C mutations in a regulatory 592 
site on chromosome 3 at positions 124,840,671 and 124,840,678 alter critical nucleotides in an 593 
IRF1 and/or PRDM1 binding site. The regulatory site lies in an intron of one isoform and 594 
promoter of an alternative isoform of SLC12A8. At the bottom, heat map displays predicted 595 
change in accessibility, considered here as DNase-seq signal in GM12865. The line plots above 596 
measure the maximum (gain) and minimum (loss) predicted change; the loss highlights 597 
nucleotides that significantly alter the overall signal upon mutation as both of these mutations do. 598 
 599 
Figure 5 - Noncoding mutations modulate luciferase gene expression.  600 
(a-c) Luciferase reporter assays of WT (black) and MUT sequences (white bars) are shown for 601 
selected NCMs associated with named genes. For each box-and-whisker plot, center line is the 602 
mean, box limits are min/max values, whiskers are s.d. Data from a representative experiment 603 
(n=3 replicates)  with a total of n=4 independent transfected cultures for each cell line are shown. 604 
P values calculated by two-tailed unpaired t test. (*, p<0.05; **, p<0.01; ***, p<0.001) 605 
 606 
Figure 6 - Gene-proximal NCMs are enriched in specific classes of CRRs. 607 
Percentage of CRRs with at least 2 mutations across the patient cohort, corrected for genome 608 
abundance and size, ordered from left to right by expression modulation score (EMS) (most 609 
repressive to most active). Dotted line represents mean mutation frequency across all CRRs.  610 
 611 
Figure 7 - Gene-proximal NCMs in repressors and activators cluster near distinct subsets 612 
of genes. 613 
(a) Pathway analysis of genes associated with recurrently mutated repressive (SUZ12, CTBP2, 614 
SETDB1) sites (red bars), versus those never harboring NCMs in those CRRs (blue bars). (b) 615 
Pathway analysis of genes associated with recurrently mutated activator (KAT2A, BCLAF1, 616 
TAF7, WRNIP1) sites (red bars), versus those never harboring NCMs in those CRRs (blue bars). 617 
AG/ND, axon guidance/neuron differentiation. 618 
 619 
Supplementary Figure 1 - Identification of recurrent noncoding mutations in PDA. 620 
Distribution of SNV rates across the patient cohort. 621 
 622 
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Supplementary Figure 2 - Overlap of SNVs and common coding mutations in PDA. 623 
Distribution of SNVs across the patient cohort, with common coding mutations (colored bars) in 624 
PDA genes. 625 
 626 
Supplementary Figure 3 - Overlap of gene-proximal NCMs in CRRs and common coding 627 
mutations in PDA. 628 
Distribution of CRR mutation rates across the patient cohort, with common coding mutations 629 
(colored bars) in PDA genes. 630 
 631 
Supplementary Figure 4 - NCMs disrupt transcription factor binding motifs. 632 
(a) A G→A mutation in a regulatory site on chromosome 15 at position 25,200,056 alters a 633 
critical nucleotide in an NRF1 binding site. The regulatory site lies in the promoter of SNRPN. At 634 
the bottom, the heat map displays the predicted change in binding, considered here as ChIP-635 
seq signal for NRF1 in H1-hESCs. The line plots above measure the maximum (gain) and 636 
minimum (loss) predicted change; the loss highlights nucleotides that significantly alter the 637 
overall signal upon mutation as this mutation does. (b) A G->T mutation in a regulatory site on 638 
chromosome 3 at position 115,757,580 introduces a GATA factor binding site nearby an 639 
established PU.1 binding site. The heat map displays the predicted change in accessibility, 640 
considered here as DNase-seq signal in K562. In other cells, such as monocytes, the model 641 
predicts reduced accessibility, suggesting that GATA binding here may alter the combinatorial 642 
logic of the regulatory element in a complex fashion. 643 
 644 
Supplementary Table 1 - Genome-wide exactly recurrent mutations in PDA. 645 
The most common exactly recurrent mutations across the patient cohort. Sequence of mutant 646 
allele in parenthesis. 647 
 648 
Supplementary Table 2 - Distribution of gene-proximal NCMs near known PDA genes. 649 
Analysis of the association of NCM clusters as determined by GECCO with known PDA genes. 650 
 651 
Supplementary Table 3 - PTPRN2 multivariate analysis. 652 
Multivariate analysis of clinico-pathological variables and PTPRN2 expression in the patient 653 
cohort. 654 
 655 
Supplementary Table 4 - CRR expression modulation scores. 656 
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Effect of CRR on activity of neighboring gene compared with all other genes in the genome (see 657 
Online Methods for analysis details). EM Score, expression modulation score.  658 
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ONLINE METHODS 659 
 660 
1. Data Acquisition 661 
All data used in this analysis were downloaded from the International Cancer Genome 662 
Consortium (IGCG) data portal (https://dcc.icgc.org/projects). At our last date of access (Feb 11, 663 
2015), simple somatic mutations (SSM) for 405 pancreatic ductal adenocarcinoma samples 664 
were available from the Australian (PACA-AU) and Canadian (PACA-CA) groups. We download 665 
the clinical data, SSMs, and when available, sequence-based gene expression (EXP-S) data for 666 
all 405 patients. 667 
 668 
2. Pre-processing 669 
The whole genome sequencing (WGS) required to call SNVs across all 405 patients and the 670 
whole genome RNA-sequencing required to calculate gene expression were carried out by two 671 
distinct consortiums, one Canadian and one Australian. All SNV calls (SSMs) and gene 672 
expression calculations (EXP-S) by these two groups were consolidated by ICGC. 673 
 674 
2.1. SNV calls from whole genome sequencing 675 
For each of the 405 patients we extracted the chromosome, start location, end location, somatic 676 
allele, and mutated allele from the list of simple somatic mutations (file: ssm_open.tsv) and 677 
converted to bed format.  Many of the SNVs were redundant within patients. For each patient, 678 
the list of SNVs were sorted by genomic coordinates and consolidated to contain only a single 679 
entry for each unique SNV. A subset of patients had extremely low numbers of SNVs (likely due 680 
to poor sequencing results) or high numbers of SNVs (likely due to hyper-mutated regions, 681 
unlocalized replication defects, or microsatellite instability). Across all 405 patients the number 682 
of unique SNVs ranged from 1 to 440,471 with a mean 7,937 and a standard deviation of 683 
26,224.  In order to remove outliers we eliminated all patients with less than 100 SNVs (92 684 
patients in total) or an SNV count more than 3 standard deviations away from the mean (5 685 
patients in total).  This left 308 patients with a mean SNV count of 7,300 and ranging from 1,040 686 
to 68,885. 687 
 688 
2.2. Gene expression (FPKM) from whole genome RNA-sequencing 689 
Of the 308 patients that passed the previous filtering step, 96 had expression data available 690 
from ICGC.  For each of the 96 patients, we extracted the normalized read count (FPKM) and 691 
Ensembl gene id (file: exp_seq.tsv). While the vast majority of genes have expression data 692 
 23
across all 96 patients, there were several thousand Ensembl genes that only contained 693 
expression data for a subset of patients.  In order to streamline and simplify downstream 694 
analysis we kept only the 50,861 Ensembl genes that were shared by all 96 patients. In addition, 695 
there were three patients (DO33168, DO35098, DO35100) that had gene expression from either 696 
2 or 3 independently sequenced samples. For these three patients, the gene expression for 697 
each gene was calculated by taking the mean across all samples. 698 
 699 
3. Analyzing noncoding variants with GECCO 700 
In order to identify potential noncoding cancer drivers, we first used FunSeq2 (v2.1.0) as a high 701 
level filter to prioritize our SNVs.  The unique SNVs for each of the 308 patients were converted 702 
to bed format and analyzed by FunSeq2 using the command ./run.sh –inf bed –n to identify only 703 
noncoding variants.  This analysis pipeline requires a suite of annotation data that is used to 704 
make calls and score noncoding variants.  These were downloaded from 705 
(http://funseq2.gersteinlab.org/data/).  One of these files, “ENCODE.annotation.gz” contains the 706 
full list of TFPs/CRRs used in our analysis along with their exact genomic coordinates. 707 
 708 
3.1 Processing recurrently mutated cis-regulatory regions (CRRs) 709 
FunSeq2 generates a number of output files including Recur.Summary, which contains a list of 710 
all noncoding elements, the genomic coordinates of these elements, the fraction of patients with 711 
a mutation in this element, and the full list of patient names along with the genomic locations of 712 
each mutation. While the ENCODE annotation data provides a number of different noncoding 713 
elements (enhancers, transcription factor binding sites (TFPs), DNase hypersensitivity, etc.) we 714 
chose to focus our analysis on TFPs – referred to in this manuscript as CRRs – as they were 715 
the most highly represented class of elements identified. CRR proximal genes were found by 716 
intersecting CRRs with genes that had been expanded by 2kb at their 5’ and 3’ ends. 717 
 718 
3.2 Calculating CRR mutation rates 719 
As described above, the full list of CRRs (121 distinct CRR classes in total) including their 720 
counts and genomic positions can be found in “ENCODE.annotation.gz.” GECCO makes two 721 
separate calculations across all 121 CRR classes using the CRR genomic information: (1) For a 722 
given CRR class, it calculates the fraction of distinct CRR sites that are mutated within the class 723 
and (2) the base level mutation rate for each CRR class (the number of mutations in all CRRs of 724 
a given class divided by the total number of base pairs of all CRRs in a given class). For an 725 
individual CRR, there are three ways in which GECCO calculates the mutational frequency: (1) 726 
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by summing the number of mutations in a given CRR, (2) by calculating the fraction of bases in 727 
the CRR that are mutated (i.e. mutation counts normalized by read length), or (3) by calculating 728 
the fraction of bases in a CRR mutation cluster. Option (3) is computed by first determining the 729 
cluster size within a CRR, the number of bases required to span all mutations in a given CRR. 730 
For example, consider a 2kb CRR with 9 mutations.  If the two most distantly separated of the 9 731 
mutations are 100bps apart then the length of the mutation cluster is 100bp. The mutational 732 
frequency of the cluster is then computed by dividing the number of mutations in that cluster by 733 
the size of the cluster (9/100 = 9.0%).  This approach weights exactly recurrent or proximal 734 
mutations more strongly than distant mutations. 735 
 736 
4. Pathway analysis 737 
The Database for Annotation, Visualization and Integrated Discovery (DAVID), a functional 738 
annotation enrichment algorithm for large-scale biological datasets was used for pathway 739 
analysis, with the following annotation categories: SP_PIR_KEYWORDS, GOTERM_BP_FAT, 740 
KEGG_PATHWAY, PANTHER_PATHWAY, SMART. A Bonferroni corrected p-value of 0.05 741 
was used as a cutoff for enrichment significance. 742 
 743 
5. Survival analysis 744 
Median survival was estimated using the Kaplan-Meier method and the difference was tested 745 
using the log-rank Test. P values of less than 0.05 were considered statistically significant. 746 
Clinico-pathologic variables analyzed with a P value of less than 0.25 on log-rank test were 747 
entered into Cox Proportional Hazard multivariate analysis, and redundant variables were 748 
eliminated using a backward elimination method. Statistical analysis was performed using 749 
StatView 5.0 Software (Abacus Systems, Berkeley, CA, USA). Overall survival (OS) or disease-750 
free survival (DFS) was used as the primary endpoint. 751 
PTPRN2 Expression level > 4.98 defined as high 752 
SLC12A8 Expression level > 7.03 defined as high 753 
 754 
6. Computing differential expression 755 
Differential expression was computed for each recurrently mutated CRR that was within 2kb of 756 
an Ensemble gene using permutation testing. For each CRR/gene pair, the 96 patients with 757 
mutation data were split into two groups – patients with mutations in the CRR and patients 758 
without mutations in the CRR.  Using the expression data downloaded from ICGC for the gene 759 
of interest a t-test is performed to generate a single t-value, the observed t-value.  The 760 
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expression values for patients with mutations in CRRs and the expression values for patients 761 
without mutations are then permuted 100,000 times to generate 100,000 additional t-values, the 762 
permuted t-values. These t-values generally fit a Gaussian distribution to which the observed t-763 
value is then compared to using a two-tailed test. The empirical p-value is computed as the 764 
fraction of times (x/100,000) that a “permuted t-value” falls further outside the Gaussian 765 
distribution than the “observed t-value”. Once p-values have been calculated for all recurrently 766 
mutated genes proximal to CRRs, GECCO estimate q-values (the false discovery rate) for each 767 
call.  This is done using the “qvalue” package in R and measures the proportion of false 768 
positives incurred given the p-value distribution. 769 
 770 
7. Luciferase Reporter Assay and Statistics 771 
150 base pair sequences surrounding specific NCMs (wild type, WT or mutant, MUT) were 772 
synthesized (Integrated DNA Technologies) and cloned into pGL4.23 (Promega), containing a 773 
minimal promoter driving firefly luciferase. Five thousand cells per well (HEK-293, MiaPaCa2 or 774 
Suit2) were co-transfected in 96-well format with the specific WT or MUT vector and pRL-775 
SV40P (Renilla luciferase, Addgene #27163) as a normalization control. Luciferase activity was 776 
measured 48 hours post-transfection with the Dual-Luciferase Reporter Assay System 777 
(Promega). Values reported are firefly luciferase divided by Renilla luciferase. Analytical 778 
statistics were generated in Prism 7.0 (GraphPad), and P values are from two-tailed unpaired t 779 
tests. All cell lines were obtained from ATCC and tested for mycoplasma contamination. 780 
 781 
8. Computing Expression Modulation Scores (EMS) 782 
Some CRRs bind transcription factors or transcription factor components with well-known 783 
expression modulation including SUZ12 and CTBP2, which act as transcriptional repressors, or 784 
BDP1 and BRF1, which act as transcriptional activators.  However, many of the 121 CRRs used 785 
in this study have unexplored or unvalidated directions of expression modulation.  We 786 
developed a method to infer the direction and effect of expression modulation for each CRR 787 
class by comparing the expression of genes proximal CRRs in a given CRR class to the mean 788 
expression of all other active genes in the genome. 789 
 790 
Many genes are inactive in any given tissue and in a given RNA-seq experiment ~50% of genes 791 
show low to no expression.  For all 96 patients with expression data, we found this also to be 792 
true with ~50% of genes showing 0 expression.  When computing the expression modulation for 793 
each CRR class we ignored all genes that showed 0 expression in at least 90% of patients (86 794 
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patients or more). For a given CRR class and for each of the 96 patients we compute (1) the 795 
mean expression of all genes proximal to CRRs in that class and (2) the mean expression of all 796 
genes non-proximal to a CRR in that class.  For a given CRR class we then compute the log of 797 
the ratio between (1) and (2) for each of the 96 patients and then take the mean of the log ratio 798 
for all 96 patients to get a single “expression modulation score” for each CRR class.  The log of 799 
the ratio will be negative if the mean expression of genes proximal to a CRR class is lower than 800 
the genome average (repression) and will be positive if the mean expression of genes proximal 801 
to a CRR class is higher than the genome average (activation).  This calculation is not meant to 802 
generate absolute numerical score for the repressive or activating activity of a CRR but is 803 
instead used to generate a rank-sorted list of CRR classes based on their expression 804 
modulation. 805 
 806 
9. Basset Analysis 807 
Basset is a recently introduced method based on convolutional neural networks to accurately 808 
predict DHSs from DNA sequence, thus enabling annotation of the influence of mutations on 809 
accessibility44. We trained the Basset deep convolutional neural network on DHSs from 164 cell 810 
types mapped by ENCODE and the Roadmap Epigenomics projects. From this, we predicted 811 
the influence of variants on the presence of DNase hypersensitivity in each cell type by 812 
computing the difference between predictions on sequences with each allele. Candidate high 813 
impact variants were further analyzed for interrupting known binding sites by converted Basset-814 
learned first convolution layer filters to probabilistic position weight matrixes by counting 815 
nucleotide occurrences in the set of sequences that activate the filter to a value that is more 816 
than half of its maximum value. We identified the likely binding protein for the motifs by querying 817 
the CIS-BP database46 (accessed on June 12, 2015) using the TomTom v4.10.1 search tool47 818 
and requiring an FDR q-value < 0.1. 819 
 820 
*All code can be requested by e-mailing MCS. 821 
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c
b FunSeq variants in pancreatic ductal adenocarcinoma (n=308)
Variant class                                                                    Total
Transcription factor binding peak/cis-regulatory region (CRR)                 264,488
Enhancer                                        19,608
DNaseI hypersensitive site                       14,572
Pseudogene                          1,632
lincRNA                           1,104
Transcription factor motif within peak                                          135
Miscellaneous RNA                               24
miRNA                                19
snRNA                                  6
snoRNA                                  4
rRNA                                   4
Figure 1 - Identification of recurrent noncoding mutations in PDA.
(a) The total number of single nucleotide variants (SNV) was plotted for each patient. (b) FunSeq2 
was utilized to detect and characterize putatitve somatic noncoding mutations from 308 PDA whole 
genome sequences. Mutation counts for each functional category are displayed. (c) The number of 
cis-regulatory region (CRR) mutations (grey bars), and CRR/total SNV (black points) were plotted 
for each patient.
a
To
ta
l S
N
V
s 
(x
10
00
)
Patient
0 
   
   
 1
0 
   
   
20
   
   
 3
0 
   
   
40
   
   
 5
0 
   
   
60
   
   
 7
0
C
R
R
 m
ut
at
io
ns
 (x
10
00
)
0 
   
   
   
   
   
  2
   
   
   
   
   
   
 4
   
   
   
   
   
   
6 
   
   
   
   
   
  8
Patient
C
R
R
/to
ta
l m
ut
at
io
ns
 (N
or
m
al
iz
ed
)
0 
   
   
   
   
  0
.5
   
   
   
   
  1
.0
   
   
   
   
  1
.5
   
   
   
   
  2
.0
Figure 2 - GECCO (Genomic Enrichment Computational Clustering Operation) flowchart.
GECCO utilizes noncoding somatic mutation calls from tumor whole genome sequencing data to identify clusters 
of mutations within 2kb of genes, including those that correlate with changes in gene expression. GECCO also 
calculates the mutation rate of gene regulatory regions and determines the strength of each regulatory region in 
terms of the effect on gene expression (expression modulation score, EMS). These data can then be used for pathway
analysis of genes flanking noncoding clusters and genes downstream of specific regulatory regions. The gene lists can 
also be interrogated for patient survival analysis when coupled to outcome data for detection of clinically relevant 
interactions.
Input whole genome sequencing data
 1) Matched tumor-normal SNV calls
2) RNA-seq expression calls
Use permutation testing
to identify CRRs
affecting expression
Pathway analysis
Patient survival analysis
FunSeq2
Prioritize non-coding regulatory variants
Associate recurrently
mutated CRRs
with flanking genes
Generate false discovery
rates
Normalize mutation
rates for GC content,
size, and abundance
Determine mutation
rates for each
regulatory class
Compute expression
modulation scores
For each CRR variant For each CRR class
Feigin et al., Figure 2
Noncoding gene-proximal mutational clusters in PDA
Feigin et al., Figure 3
CRR                 Nearest gene    Patients (%)         Gene name/protein function     shRNA
TCF12        LHX8  17 (5.52%) LIM homeobox 8      Yes
JUND  LINC01194 16 (5.19%) long intergenic non-protein coding RNA    NA
E2F1        BMP7  15 (4.87%) bone morphogenetic protein 7     No
SUZ12        LHX8  15 (4.87%) LIM homeobox 8      
WRNIP1        DUSP22  15 (4.87%) dual specificity phosphatase 22    No
EP300  REREP3  14 (4.55%) arginine-glutamic acid dipeptide (RE) repeats pseudogene 3  NA
SUZ12        LMX1B  14 (4.55%) LIM homeobox txn factor     Yes (P)
SUZ12        PAX6  14 (4.55%) paired box 6, homeodomain     Yes
TCF12  ZIC4  14 (4.55%) zinc-finger family member 4     No
HDAC2  FANK1  14 (4.55%) fibronectin type 3 and ankyrin repeat domains 1   No
FOXA1  REREP3  13 (4.22%) arginine-glutamic acid dipeptide (RE) repeats pseudogene 3  NA
NFKB1, POU2F2 ST8SIA4  13 (4.22%) ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 No
SIN3A  MIR21  13 (4.22%) microRNA21      NA
SIN3A  VMP1  13 (4.22%) vacuole membrane protein 1     No
SUZ12        DMRTA2  13 (4.22%) doublesex-and Mab-3-related transcription factor A2  Yes
SUZ12  VAX2  13 (4.22%) ventral anterior homeobox 2     Yes
SUZ12  ZIC4  13 (4.22%) zinc-finger family member 4     
BCLAF1        DUSP22  12 (3.90%) dual specificity phosphatase 22    
BCLAF1  MALAT1  12 (3.90%) Metastasis Associated Lung Adenocarcinoma Transcript 1 (lncRNA) NA
BCLAF1  VMP1  12 (3.90%) vacuole membrane protein 1     
CDH2, JUND ZNF595  12 (3.90%) zinc-finger txn factor     No
CDH2, JUND ZNF718  12 (3.90%) zinc-finger txn factor     No
FOXA1        CDH15  12 (3.90%) cadherin 15, type 1, M-cadherin    Yes (P)
HDAC2  CDH8  12 (3.90%) cadherin 8, type 2      No
Figure 3 - Clustered gene-proximal mutations and pathways in PDA.
(a) The most common mutational clusters across the patient cohort as determined by GECCO, with associated 
genes; Yes = knockdown promoted cell death in shRNA cancer cell line screen. (P denotes PDA-specific); 
No = no evidence for effect on cell death in shRNA cancer cell line screen; CRR=FunSeq2-defined cis-regulatory 
region. (b) Most significant clusters when corrected for cluster size as determined by GECCO. (c) DAVID pathway 
analysis was used to identify regulatory processes and pathways from genes associated with recurrent NCMs. 
Corrected for bounded gene-proximal CRR
CRR         Nearest gene         Patients (%)         Cluster (bp)         Mutation freq. (%)       Gene name/protein function   
BHLHE40         ACOXL       5 (1.62%)    1               >100   acyl-CoA oxidase-like
RAD21          NRXN3       5 (1.62%)    19               26.32                 neurexin 3, neuronal cell adhesion
MAFK               MACROD2            5 (1.62%)    55               9.09                  O-acetyl-ADP-ribose deacetylase
EGR1          ARSD       5 (1.62%)    65               7.69                  arylsulfatase D
REST          LILRA5       5 (1.62%)    81               6.17                  leukocyte immunoglobulin-like receptor
CEBPB          PDE4B       6 (1.95%)    129               4.65                  phosphodiesterase 4B, cAMP-specific
NRF1          ANXA11       5 (1.62%)    134               3.73                  annexin A11
GATA2          XKR6       5 (1.62%)    145               3.45                  Kell blood group complex-related
NR3C1          PXDN       7 (2.27%)    223               3.14                  phroxidasin Homolog
JUND          NBPF25P       5 (1.62%)    162               3.09                  neuroblastoma breakpoint family, pseudogene
STAT3          SORCS1       6 (1.95%)    205               2.93                  sortilin-related VPS10 domain containing receptor
USF1          SCAI       5 (1.62%)    171               2.92                  suppressor of cancer cell invasion
BRF2          FRG1B       5 (1.62%)    186               2.69                  FSHD region gene 1 family, lncRNA
CEBPB             NRXN1       5 (1.62%)    227               2.20                  neurexin 1, neuronal cell adhesion
ZNF263          LINC00693       6 (1.95%)    283               2.12                  uncharacterized lncRNA
Pathways regulated by NCMs in pancreatic ductal adenocarcinoma
Regulatory process/gene family # genes altered p-value        Representative altered genes
Regulation of transcription  135  3.9E-15  ALX4, DMRTA2, T, TWIST1, RUNX3, WWTR1
Homeobox   45  6.2E-26  LHX5, NKX2-8, HOXB4, IRX1, MSX1, VAX2
Neuron differentiation/axon guidance 53  1.1E-19  ROBO1, SLIT2, NRXN1, CTNNA2, NCAM2, BDNF
Cell adhesion   24  2.8E-4  CDH15, CDH8, CADM1, ITGB2, LAMA5, CNTN4
Wnt signaling pathway  18  4.3E-2  FZD10, FBXW11, NKD1, TCF7L1, EN2
a
b
c
CRR (MUT#) Nearest gene    MUT allele     WT allele      Fold change   p-value        q-value
NCMs correlate with gene expression changes Feigin et al., Figure 4
MAX (5)       PTPRN2           0.82      10.92           0.075   0.00593         0.09689 
FOSL2 (7)      KCNQ1           0.85      6.39           0.133   0.02456         0.18212
TAF7 (9)       SNRPN           0.46      3.4           0.135   0.00818         0.11818
NFKB1 (7) GYPC           1.08      7.29           0.148   0.01845         0.15157
TAF1 (6)       PDPN           2.09      13.08           0.160   0.03544         0.22016
BCLAF1 (5)      PRSS12           1.07      6.46           0.166   0.01107         0.14144
MAFK (3)       SOX5           0.29      1.63           0.178   0.02851         0.20379
POU2F2 (6)      MIR4420           8.16      40.24           0.203   0.01773         0.15157
WRNIP1 (3)      IKZF1           0.64      3.15           0.203   0.01811         0.15157
GATA3 (3)      PCLO           0.35      1.67           0.210   0.01113         0.14144
JUND (3)       TUSC7           0.98      4.53           0.216   0.02909         0.20560
REST (3)       MTERF4           1.46      5.78           0.253   0.02209         0.16542
GATA1 (3)      FNIP2           7.59      18.32           0.414   0.02588         0.18929
CEBPB (3)      PNPLA8           5.69      13.62           0.418   0.01726         0.15157
EGR1 (5)       SLC12A8           4.34      7.99           0.542   0.04185         0.23823         
SIN3A (3)       FAM192A           20.31      30.48           0.666   0.01788         0.15157
a
Figure 4 - Recurrent gene-proximal mutations correlate with gene expression changes in PDA. 
(a) GECCO used gene expression data from matched PDA patients to correlate NCMs with changes in gene expression “Mut 
allele” = mean expression of linked gene in patients with associated CRR mutations. “WT allele” = mean expression of linked 
gene in patients without associated CRR mutations. (b) Analysis of overall survival (OS) in PDA patients expressing high 
(upper 2/3) and low (lower 1/3) levels of PTPRN2. Purple dots represent patients with high expression of PTPRN2 “at risk” 
(alive). Red dots represent patients with low expression of PTPRN2 “at risk” (alive). (c) Analysis of disease-free survival (DFS) 
in PDA patients expressing high (upper 2/3) and low (lower 1/3) levels of SLC12A8. (d) Two A→C mutations in a regulatory site 
on chromosome 3 at positions 124,840,671 and 124,840,678 alter critical nucleotides in an IRF1 and/or PRDM1 binding site. 
The regulatory site lies in an intron of one isoform and promoter of an alternative isoform of SLC12A8. At the bottom, heat map 
displays predicted change in accessibility, considered here as DNase-seq signal in GM12865. The line plots above measure 
the maximum (gain) and minimum (loss) predicted change; the loss highlights nucleotides that significantly alter the overall signal 
upon mutation as both of these mutations do.
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Figure 5 - Noncoding mutations modulate luciferase gene expression. 
(a-c) Luciferase reporter assays of WT (black) and MUT sequences (white bars) are shown for selected NCMs 
associated with named genes. For each box-and-whisker plot, center line is the mean, box limits are min/max values, 
whiskers are standard error of the mean.  (*, p<0.05; **, p<0.01; ***, p<0.001)
Feigin et al., Figure 5
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Figure 6 - Gene-proximal NCMs are enriched in specific classes of CRRs.
Percentage of CRRs with at least 2 mutations across the patient cohort, corrected for genome abundance 
and size, ordered from left to right by expression modulation score (EMS) (most repressive to most active). 
Dotted line represents mean mutation frequency across all CRRs. 
Feigin et al., Figure 7
Figure 7 - Gene-proximal NCMs in repressors and activators cluster near distinct sets of genes.
(a) Pathway analysis of genes associated with recurrently mutated repressive (SUZ12, CTBP2, SETDB1) 
sites (red bars), versus those never harboring NCMs in those CRRs (blue bars). (b) Pathway analysis of 
genes associated with recurrently mutated activator (KAT2A, BCLAF1, TAF7, WRNIP1) sites (red bars), 
versus those never harboring NCMs in those CRRs (blue bars). AG/ND, axon guidance/neuron differentiation.
b
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Supplementary Figure 1 - Identification of recurrent noncoding mutations in PDA.
Distribution of SNV rates across the patient cohort.
Feigin et al., Supp Figure 2
Supplementary Figure 2 - Overlap of SNVs and common coding mutations in PDA.
Distribution of SNVs across the patient cohort, with common coding mutations (colored bars) 
in PDA genes.
M
ut
at
io
n 
co
un
t (
x1
00
0)
Patient
0 
   
 1
0 
   
  2
0 
   
30
   
  4
0 
   
 5
0 
   
 6
0 
   
70
Distribution of SNV rates across patients 
with KRAS coding mutations
M
ut
at
io
n 
co
un
t (
x1
00
0)
Patient
0 
   
 1
0 
   
 2
0 
   
 3
0 
   
 4
0 
   
 5
0 
   
 6
0 
   
70
Distribution of SNV rates across patients 
with TP53 coding mutations
M
ut
at
io
n 
co
un
t (
x1
00
0)
Patient
0 
   
 1
0 
   
  2
0 
   
30
   
  4
0 
   
 5
0 
   
 6
0 
   
70
Distribution of SNV rates across patients 
with CDKN2A coding mutations
M
ut
at
io
n 
co
un
t (
x1
00
0)
Patient
0 
   
 1
0 
   
  2
0 
   
30
   
  4
0 
   
 5
0 
   
 6
0 
   
70
Distribution of SNV rates across patients 
with ARID1A coding mutations
M
ut
at
io
n 
co
un
t (
x1
00
0)
Patient
0 
   
 1
0 
   
  2
0 
   
30
   
  4
0 
   
 5
0 
   
 6
0 
   
70
Distribution of SNV rates across patients 
with SMAD4 coding mutations
KRAS coding mutation TP53 coding mutation
CDKN2A coding mutation SMAD4 coding mutation
ARID1A coding mutation
Feigin et al., Supp Figure 3
Supplementary Figure 3 - Overlap of gene-proximal NCMs in CRRs and common coding mutations in PDA.
Distribution of CRR mutation rates across the patient cohort, with common coding mutations (colored bars) 
in PDA genes.
M
ut
at
io
n 
co
un
t (
x1
00
0)
Patient
0 
   
   
   
   
2 
   
   
   
   
4 
   
   
   
   
 6
   
   
   
   
 8
Distribution of CRR mutation rates across 
patients with KRAS coding mutations
M
ut
at
io
n 
co
un
t (
x1
00
0)
Patient
0 
   
   
   
   
 2
   
   
   
   
 4
   
   
   
   
 6
   
   
   
   
 8
Distribution of CRR mutation rates across 
patients with TP53 coding mutations
M
ut
at
io
n 
co
un
t (
x1
00
0)
Patient
0 
   
   
   
   
 2
   
   
   
   
 4
   
   
   
   
 6
   
   
   
   
 8
Distribution of CRR mutation rates across 
patients with CDKN2A coding mutations
M
ut
at
io
n 
co
un
t (
x1
00
0)
Patient
0 
   
   
   
   
 2
   
   
   
   
 4
   
   
   
   
 6
   
   
   
   
 8
Distribution of CRR mutation rates across 
patients with ARID1A coding mutations
M
ut
at
io
n 
co
un
t (
x1
00
0)
Patient
0 
   
   
   
   
2 
   
   
   
   
4 
   
   
   
   
 6
   
   
   
   
 8
Distribution of CRR mutation rates across 
patients with SMD4 coding mutations
KRAS coding mutation TP53 coding mutation
CDKN2A coding mutation SMAD4 coding mutation
ARID1A coding mutation
Feigin et al., Supp Figure 4
SNRPN
25.1994 mb 25.1995 mb 25.1996 mb 25.1997 mb 25.1998 mb 25.1999 mb 25.2 mb 25.2001 mb 25.2002 mb 25.2003 mb 25.2004 mb 25.2005 mb 25.2006 mb 25.2007 mb
0
5
10
15
20
25
PA
N
C
−1
D
N
as
e−
se
q
Ge
ne
s
0 20 40 60 80 100 120
0.0
0.2
0.4
0.6 loss
gain
T
G
C
A
−0.4
−0.2
0.0
0.2
0.4
0
1
2
bi
ts
1TC
A
G
2GT
A
C
3T
C
A
G
4AT
G
C
5G
A
C
6AC
G
T
7A
C
T
G
8A
G
T
C
9A
T
C
G
10
G
T
A
C
11
C
G
A
CIS-BP
NRF1
0 20 40 60 80 100 120
0.00
0.05
0.10
0.15
0.20
loss
gain
T
G
C
A
−0.16
−0.08
0.00
0.08
0.16
1
2
bi
ts
AGATAA
115.74 mb 115.75 mb 115.76 mb 115.77 mb
0
2
4
6
8
10
12
PA
N
C
−1
D
N
as
e−
se
q
Ge
ne
s LSAMP
CIS-BP
GATA4
a
b
Supplementary Figure 4 - NCMs disrupt transcription factor binding motifs.
(a) A G→A mutation in a regulatory site on chromosome 15 at position 25,200,056 alters a critical nucleotide in an NRF1 
binding site. The regulatory site lies in the promoter of SNRPN. At the bottom, the heat map displays the predicted change in 
binding, considered here as ChIP-seq signal for NRF1 in H1-hESCs. The line plots above measure the maximum (gain) and 
minimum (loss) predicted change; the loss highlights nucleotides that significantly alter the overall signal upon mutation as this 
mutation does. (b) A G->T mutation in a regulatory site on chromosome 3 at position 115,757,580 introduces a GATA factor 
binding site nearby an established PU.1 binding site. The heat map displays the predicted change in accessibility, considered 
here as DNase-seq signal in K562. In other cells, such as monocytes, the model predicts reduced accessibility, suggesting that 
GATA binding here may alter the combinatorial logic of the regulatory element in a complex fashion.
Feigin et al., Supp Table 1
Supplementary Table 1 - Exactly recurrent mutations in PDA.
The most common exactly recurrent mutations across the patient cohort. Sequence of mutant allele in parenthesis. 
Genome-wide exactly recurrent (n≥6) noncoding mutations in PDA
Nearest gene Patients (%)     Sequence Gene name/protein function 
COX7B2  7 (2.27)  GTCA(T)TA cytochrome c oxidase subunit
OSBPL9  7 (2.27)  ATTA(T)AT oxysterol binding protein-like 9; cholesterol transfer protein
WASF3  7 (2.27)  TTTT(A)AA Wiskott-Aldrich syndrome protein family
ZNF81  7 (2.27)  AATA(T)AA zinc finger protein; transcription factor
BNC2  6 (1.95)  TTTA(T)AA basonuclin 2; zinc finger transcription factor
ELMO1  6 (1.95)  TTTA(T)AA engulfment and cell motility 1; cytoskeletal rearrangement
GPR98  6 (1.95)  TCTC(A)TC G protein-coupled receptor; central nervous system development
MYO16  6 (1.95)  GCTT(C)GC myosin XVI; actin-based motor with ATPase activity
PDE3B  6 (1.95)  ATAG(T)AG phosphodiesterase 3B; regulates cAMP binding of RAPGEF3
SOX5  6 (1.95)  ATAG(T)AG SRY (sex determining region Y)-box 5; transcription factor
TMEM232 6 (1.95)  ATAG(T)AG transmembrane protein 232
NCM overlap with known PDA genes
PDA gene     CRR (# patients)  
KRAS    -
TP53    -
CDKN2A    -
SMAD4    -
ARID1A    -
MLL3    -
PIK3CA    -
MAP2K4    -
BRAF    -
ZIM2            JUND (6)
PEG3   TAF1 (6), FOSL2 (5)
NEB    -
FLG    -
TGFBR2    -
ATM    -
HMCN1    -
ACVR1B    -
XIRP2    -
APC    -
FBXW7    -
RB1    -
USP47    -
BRCA2    -
PALB2    -
LKB1    -
PRSS1    -
Feigin et al., Supp Table 2
Supplementary Table 2 - Distribution of gene-proximal NCMs near known PDA genes.
Analysis of the association of NCM clusters with known PDA genes.
Feigin et al., Supp Table 3
Supplementary Table 3 - PTPRN2 multivariate analysis.
Multivariate analysis of clinico-pathological variables and PTPRN2 expression in the patient cohort.
Multivariate Analysis 
 Variable Hazard Ratio (95% CI) P Value 
    
A. Clinico-pathological and 
PTPRN2  
(n = 254, Starting model) 
Sex (Male) 1.16 (0.83 – 1.62) 0.3933 
Lymph Node Metastases (Positive) 1.08 (0.65 – 1.81) 0.7561 
Grade (G3/4) 1.68 (1.19 – 2.38) 0.0033 
Tumor Size (> 20 mm) 1.90 (1.04 – 3.50) 0.0378 
Margin Involvement (Positive) 1.25 (0.87 – 1.81) 0.2208 
Tumor Location (Body/Tail) 1.71 (1.15 – 2.54) 0.0078 
Perineural Invasion (Positive) 1.48 (0.88 – 2.51) 0.1416 
Vascular Invasion (Positive) 1.65 (1.07 – 2.54) 0.0227 
PTPRN2 Expression (Low) 1.42 (1.00 – 2.01) 0.0505 
   
B. Clinico-pathological and 
PTPRN2 
(Final model) 
Grade (G3/4) 1.69 (1.21 – 2.38) 0.0021 
Tumor Size (> 20 mm) 1.98 (1.10 – 3.60) 0.0239 
Tumor Location (Body/Tail) 1.87 (1.26 – 2.75) 0.0017 
Vascular Invasion (Positive) 2.05 (1.44 – 2.92) <0.0001 
PTPRN2 Expression (Low) 1.43 (1.00 – 2.02) 0.0453 
   
Feigin et al., Supp Table 4
Supplementary Table 4 - CRR expression modulation scores.
Effect of CRR on activity of neighboring gene compared with all other genes in the genome (see Online Methods 
for analysis details). EM Score, expression modulation score.
CRR          EM Score                 CRR            EM Score                CRR            EM Score
SUZ12 -0.686694944 HDAC2 0.150381608 RXRA 0.273722674
CTBP2 -0.674670553 E2F6 0.150409791 HMGN3 0.281526015
POU5F1 -0.56033248 BHLHE40 0.151537078 NFKB1 0.288817568
ZNF274 -0.245849532 POLR3A 0.159325596 ZEB1 0.303120139
ZZZ3 -0.161998971 JUN 0.162188074 ETS1 0.310574829
BATF -0.135543815 EBF1 0.163190758 TAF7 0.313174867
MAFF -0.075863388 TRIM28 0.163945818 CHD2 0.315050091
ESR1 -0.039131089 TFAP2A 0.164300299 JUNB 0.325497894
NANOG -0.038471214 ZNF143 0.169254105 ATF3 0.326109056
ZBTB33 -0.030552156 STAT1 0.171479031 NRF1 0.326352606
ZNF263 -0.025572293 GABPA 0.172425715 POU2F2 0.327706868
MAFK -0.02294752 HSF1 0.176973018 SRF 0.337389028
REST -0.003580494 PBX3 0.177027193 NFE2 0.342471413
SIRT6 0.002156973 FOS 0.17863575 SMARCB1 0.345768127
RAD21 0.009059509 NR3C1 0.178665134 SIN3A 0.354604782
HNF4A 0.02493997 YY1 0.179418835 TAF1 0.363204782
NR2C2 0.030842166 SMARCA4 0.187416973 BRF1 0.364973559
FOXA2 0.035231355 SP1 0.189263356 RFX5 0.372691206
FOXA1 0.036020516 IRF4 0.189407346 SREBF2 0.380044338
BCL11A 0.040986649 ELF1 0.190484821 BDP1 0.396235351
MEF2C 0.046893332 SMARCC1 0.196306055 SIX5 0.402922065
HNF4G 0.047321602 TCF4 0.196772009 SP2 0.411373792
GATA3 0.056356258 EP300 0.198545703 BRCA1 0.420438253
CTCF 0.057809323 PAX5 0.199920331 PRDM1 0.421602184
CEBPB 0.069849107 NFYB 0.20623068 E2F4 0.421865085
TAL1 0.071199973 GATA1 0.207466124 IRF1 0.433584837
SPI1 0.085668185 E2F1 0.209186604 BCLAF1 0.433812837
SETDB1 0.093669622 FOSL2 0.220324569 MXI1 0.436922274
ZBTB7A 0.097578103 USF2 0.221126568 KAT2A 0.451063271
GATA2 0.098239781 TBP 0.227528399 IRF3 0.475299075
SMC3 0.103732676 ESRRA 0.230647673 SMARCC2 0.479021415
MYC 0.103926411 TFAP2C 0.231536652 ELK4 0.490643603
BCL3 0.112807799 SREBF1 0.240511397 THAP1 0.493514238
MAX 0.116546688 HDAC8 0.241186695 STAT2 0.524018361
EGR1 0.119910439 TCF12 0.251270827 GTF2B 0.544751967
USF1 0.120445295 CCNT2 0.263950123 FAM48A 0.567152197
CTCFL 0.129630002 NFYA 0.267597423 GTF2F1 0.669284919
MEF2A 0.130585096 STAT3 0.268609945 WRNIP1 0.693109157
JUND 0.132604078 FOSL1 0.268875227 RDBP 1.123049853
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Results 
 
Somatic mutation calling 
SNVs were called using BWA and GATK as previously described1. The rates and 
distribution of coding mutations in commonly mutated PDA genes (KRAS, TP53, 
CDKN2A, SMAD4, ARID1A) in the patient cohort was consistent with previous reports 
(Supplementary Fig. 2). We confirmed somatic status of the variants by searching for 
any evidence of the putative tumor variant in whole genome sequences of matched 
normal tissue for each patient. 
 
Depletion of SNPs 
Cancer mutations are depleted in accessible regulatory regions, particularly in those of 
the originating cell type2. Our set of SNPs was similarly depleted in DHSs from 164 cell 
types mapped by ENCODE and the Roadmap Epigenomics projects. The top ten most 
depleted DHS sets were from blood cells, for which >1.5 times fewer SNPs were present 
than after shuffling. Mapped cell types related to the pancreas were also depleted but 
inconspicuous in the broader context of many other cell types. 
 
General feature of FunSeq2 
The FunSeq2 pipeline filters cancer variants to exclude common polymorphisms from 
the 1000 Genomes project and retain those in noncoding regions. Further filters select 
for non-coding mutations in “sensitive” regions (those under strong negative selection), 
regions of high centrality in the protein-protein interaction network, ENCODE-defined 
regions captured by chromatin immunoprecipitation (ChIP), and mutations disrupting 
transcription factor binding motifs. We confirmed the somatic status of the mutations by 
comparing with matched normal DNA for each patient. 
 
Enrichment of NCMs in CRRs 
Noncoding mutations were found to be specifically enriched in certain classes of gene-
proximal CRRs, including binding regions for the RNA Polymerase III Transcription 
Initiation Factors BRF1 and BDP1, the Polycomb Repressive Complex 2 component 
SUZ12, the lysine acetyltransferase KAT2A, the negative elongation factor of RNA 
Polymerase II RDBP, and the transcriptional repressor CTBP2. 
 
Discussion 
The number of NCM-gene expression associations we uncover in this study is higher 
than that of similar whole genome cancer analyses. Several differences may account for 
this finding. First, we focused exclusively on a large number of samples from a single 
cancer type, rather than including a diverse array of cancers. As recurrent somatic 
NCMs are relatively uncommon (as are most coding mutations in PDA), reducing the 
heterogeneity of the samples allows detection of rare events. Second, we used GECCO 
to select those NCMs that are most likely to cause alterations in gene expression and 
focused on clusters of mutations within specific regulatory regions in close proximity to 
genes.  
 
We provide evidence that NCMs in specific regulatory element classes are selected for 
during tumor evolution. These highly mutated regulatory element classes are 
predominantly those with the greatest impact on gene expression. Further research will 
be required to uncover if these regions are actively promoting or repressing gene 
expression in PDA, or if they are independently associated with highly expressed or 
repressed genes. 
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